JP Morgan Call 1210 REGN 15.11.20.../ DE000JT68WU5 /
| 10/4/2024 8:37:04 AM | Chg.-0.011 | Bid9:31:26 PM | Ask9:31:26 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.041EUR | -21.15% | 0.037 Bid Size: 50,000 |
0.057 Ask Size: 50,000 |
Regeneron Pharmaceut... | 1,210.00 USD | 11/15/2024 | Call |
GlobeNewswire
8/26
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire
8/26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
8/15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
8/15
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire
8/12
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
8/8
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...
GlobeNewswire
8/7
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire
7/31
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire
7/23
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
7/23
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire
7/16
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
GlobeNewswire
7/10
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire
7/7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
7/3
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire
7/3
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GlobeNewswire
6/30
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
6/28
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire
6/27
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire
6/26
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
